A citation-based method for searching scientific literature

Kent C Shih, Sajeel Chowdhary, Paul Rosenblatt, Alva B Weir, Gregg C Shepard, Jeffrey T Williams, Mythili Shastry, Howard A Burris, John D Hainsworth. J Neurooncol 2016
Times Cited: 50







List of co-cited articles
473 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Thomas J Kaley, Patrick Wen, David Schiff, Keith Ligon, Sam Haidar, Sasan Karimi, Andrew B Lassman, Craig P Nolan, Lisa M DeAngelis, Igor Gavrilovic,[...]. Neuro Oncol 2015
143
72

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series.
Emil Lou, Ashley L Sumrall, Scott Turner, Katherine B Peters, Annick Desjardins, James J Vredenburgh, Roger E McLendon, James E Herndon, Frances McSherry, Julie Norfleet,[...]. J Neurooncol 2012
114
60

Atypical and anaplastic meningiomas treated with bevacizumab.
Lakshmi Nayak, Fabio M Iwamoto, Jeremy D Rudnick, Andrew D Norden, Eudocia Quant Lee, Jan Drappatz, Antonio Omuro, Thomas J Kaley. J Neurooncol 2012
110
60

Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.
Thomas Kaley, Igor Barani, Marc Chamberlain, Michael McDermott, Katherine Panageas, Jeffrey Raizer, Leland Rogers, David Schiff, Michael Vogelbaum, Damien Weber,[...]. Neuro Oncol 2014
125
50

Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.
Victoria E Clark, E Zeynep Erson-Omay, Akdes Serin, Jun Yin, Justin Cotney, Koray Ozduman, Timuçin Avşar, Jie Li, Phillip B Murray, Octavian Henegariu,[...]. Science 2013
486
46

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
44

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.
Priscilla K Brastianos, Peleg M Horowitz, Sandro Santagata, Robert T Jones, Aaron McKenna, Gad Getz, Keith L Ligon, Emanuele Palescandolo, Paul Van Hummelen, Matthew D Ducar,[...]. Nat Genet 2013
377
42

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
Marianne F James, Sangyeul Han, Carolyn Polizzano, Scott R Plotkin, Brendan D Manning, Anat O Stemmer-Rachamimov, James F Gusella, Vijaya Ramesh. Mol Cell Biol 2009
185
38

A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.
Jeffrey J Raizer, Sean A Grimm, Alfred Rademaker, James P Chandler, Kenji Muro, Irene Helenowski, Laurie Rice, Katie McCarthy, Sandra K Johnston, Maciej M Mrugala,[...]. J Neurooncol 2014
61
38

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
Felix Sahm, Daniel Schrimpf, Damian Stichel, David T W Jones, Thomas Hielscher, Sebastian Schefzyk, Konstantin Okonechnikov, Christian Koelsche, David E Reuss, David Capper,[...]. Lancet Oncol 2017
330
36

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.
Malak Abedalthagafi, Wenya Linda Bi, Ayal A Aizer, Parker H Merrill, Ryan Brewster, Pankaj K Agarwalla, Marc L Listewnik, Dora Dias-Santagata, Aaron R Thorner, Paul Van Hummelen,[...]. Neuro Oncol 2016
148
34

Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.
Yongli Ji, Cathryn Rankin, Steven Grunberg, Andy E Sherrod, Jamshid Ahmadi, Jeannette J Townsend, Lynn G Feun, Ruth K Fredericks, Christy A Russell, Fairooz F Kabbinavar,[...]. J Clin Oncol 2015
65
34

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Thomas Graillon, Marc Sanson, Chantal Campello, Ahmed Idbaih, Matthieu Peyre, Hadrien Peyrière, Noémie Basset, Didier Autran, Catherine Roche, Michel Kalamarides,[...]. Clin Cancer Res 2020
39
43

mTORC1 inhibitors suppress meningioma growth in mouse models.
Doreen Pachow, Nadine Andrae, Nadine Kliese, Frank Angenstein, Oliver Stork, Annette Wilisch-Neumann, Elmar Kirches, Christian Mawrin. Clin Cancer Res 2013
68
32

TERT Promoter Mutations and Risk of Recurrence in Meningioma.
Felix Sahm, Daniel Schrimpf, Adriana Olar, Christian Koelsche, David Reuss, Juliane Bissel, Annekathrin Kratz, David Capper, Sebastian Schefzyk, Thomas Hielscher,[...]. J Natl Cancer Inst 2015
188
32

EANO guidelines for the diagnosis and treatment of meningiomas.
Roland Goldbrunner, Giuseppe Minniti, Matthias Preusser, Michael D Jenkinson, Kita Sallabanda, Emmanuel Houdart, Andreas von Deimling, Pantelis Stavrinou, Florence Lefranc, Morten Lund-Johansen,[...]. Lancet Oncol 2016
377
32

Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
Marc C Chamberlain, Michael J Glantz, Camilo E Fadul. Neurology 2007
120
32


Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.
Victoria E Clark, Akdes Serin Harmancı, Hanwen Bai, Mark W Youngblood, Tong Ihn Lee, Jacob F Baranoski, A Gulhan Ercan-Sencicek, Brian J Abraham, Abraham S Weintraub, Denes Hnisz,[...]. Nat Genet 2016
171
28

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Andrew D Norden, Keith L Ligon, Samantha N Hammond, Alona Muzikansky, David A Reardon, Thomas J Kaley, Tracy T Batchelor, Scott R Plotkin, Jeffrey J Raizer, Eric T Wong,[...]. Neurology 2015
51
28

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, Andrew D Norden, Timothy F Cloughesy, Lauren E Abrey, Howard A Fine, Susan M Chang, H Ian Robins, Karen Fink,[...]. Neuro Oncol 2009
90
28

Temozolomide for treatment-resistant recurrent meningioma.
Marc C Chamberlain, Denice D Tsao-Wei, Susan Groshen. Neurology 2004
101
28

Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
Marta Simó, Andreas A Argyriou, Miquel Macià, Gerard Plans, Carles Majós, Noemi Vidal, Miguel Gil, Jordi Bruna. Cancer Chemother Pharmacol 2014
40
35

Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.
M H Ruttledge, J Sarrazin, S Rangaratnam, C M Phelan, E Twist, P Merel, O Delattre, G Thomas, M Nordenskjöld, V P Collins. Nat Genet 1994
443
26

Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review.
Leland Rogers, Igor Barani, Marc Chamberlain, Thomas J Kaley, Michael McDermott, Jeffrey Raizer, David Schiff, Damien C Weber, Patrick Y Wen, Michael A Vogelbaum. J Neurosurg 2015
304
26

BAP1 mutations in high-grade meningioma: implications for patient care.
Ganesh M Shankar, Sandro Santagata. Neuro Oncol 2017
80
26

Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.
Julia Furtner, Veronika Schöpf, Katharina Seystahl, Emilie Le Rhun, Roberta Rudà, Ulrich Roelcke, Susanne Koeppen, Anna Sophie Berghoff, Christine Marosi, Paul Clement,[...]. Neuro Oncol 2016
36
36

Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
Fabio P Nunes, Vanessa L Merker, Dominique Jennings, Paul A Caruso, Emmanuelle di Tomaso, Alona Muzikansky, Fred G Barker, Anat Stemmer-Rachamimov, Scott R Plotkin. PLoS One 2013
61
24

SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Julien Boetto, Franck Bielle, Marc Sanson, Matthieu Peyre, Michel Kalamarides. Neuro Oncol 2017
51
24

Medical therapies for meningiomas.
Patrick Y Wen, Eudocia Quant, Jan Drappatz, Rameen Beroukhim, Andrew D Norden. J Neurooncol 2010
101
24

Genomic landscape of high-grade meningiomas.
Wenya Linda Bi, Noah F Greenwald, Malak Abedalthagafi, Jeremiah Wala, Will J Gibson, Pankaj K Agarwalla, Peleg Horowitz, Steven E Schumacher, Ekaterina Esaulova, Yu Mei,[...]. NPJ Genom Med 2017
85
24


Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
Andrew D Norden, Jeffrey J Raizer, Lauren E Abrey, Kathleen R Lamborn, Andrew B Lassman, Susan M Chang, W K Alfred Yung, Mark R Gilbert, Howard A Fine, Minesh Mehta,[...]. J Neurooncol 2010
108
24

Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
David E Reuss, Rosario M Piro, David T W Jones, Matthias Simon, Ralf Ketter, Marcel Kool, Albert Becker, Felix Sahm, Stefan Pusch, Jochen Meyer,[...]. Acta Neuropathol 2013
146
22

High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.
Stéphane Goutagny, Jean C Nault, Maxime Mallet, Dominique Henin, Jessica Z Rossi, Michel Kalamarides. Brain Pathol 2014
158
22

Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Ümmügülsüm Yesilöz, Elmar Kirches, Christian Hartmann, Johannes Scholz, Siegfried Kropf, Felix Sahm, Makoto Nakamura, Christian Mawrin. Neuro Oncol 2017
47
23

Advances in meningioma genetics: novel therapeutic opportunities.
Matthias Preusser, Priscilla K Brastianos, Christian Mawrin. Nat Rev Neurol 2018
78
22

Trabectedin has promising antineoplastic activity in high-grade meningioma.
Matthias Preusser, Sabine Spiegl-Kreinecker, Daniela Lötsch, Adelheid Wöhrer, Maria Schmook, Karin Dieckmann, Walter Saringer, Christine Marosi, Walter Berger. Cancer 2012
43
23

Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas.
Ganesh M Shankar, Malak Abedalthagafi, Rachael A Vaubel, Parker H Merrill, Naema Nayyar, Corey M Gill, Ryan Brewster, Wenya Linda Bi, Pankaj K Agarwalla, Aaron R Thorner,[...]. Neuro Oncol 2017
67
20

Salvage chemotherapy with CPT-11 for recurrent meningioma.
Marc C Chamberlain, Denice D Tsao-Wei, Susan Groshen. J Neurooncol 2006
64
20

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
Derek R Johnson, David W Kimmel, Patrick A Burch, Terrence L Cascino, Caterina Giannini, Wenting Wu, Jan C Buckner. Neuro Oncol 2011
52
20


Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab.
S Goutagny, E Raymond, O Sterkers, J M Colombani, M Kalamarides. Ann Oncol 2011
39
25

Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
Christian Mawrin, Tina Sasse, Elmar Kirches, Siegfried Kropf, Thomas Schneider, Christoph Grimm, Claudia Pambor, Christian K Vorwerk, Raimund Firsching, Uwe Lendeckel,[...]. Clin Cancer Res 2005
91
18

Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363.
Michael Weller, Patrick Roth, Felix Sahm, Isabel Burghardt, Bernhard Schuknecht, Elisabeth J Rushing, Luca Regli, Justin P Lindemann, Andreas von Deimling. J Natl Cancer Inst 2017
28
32

Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea.
U M Schrell, M G Rittig, M Anders, U H Koch, R Marschalek, F Kiesewetter, R Fahlbusch. J Neurosurg 1997
132
18

Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Elena Mazza, Alba Brandes, Silvia Zanon, Marika Eoli, Giuseppe Lombardi, Marina Faedi, Enrico Franceschi, Michele Reni. Cancer Chemother Pharmacol 2016
23
39

Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review.
Thomas Graillon, David Romano, Céline Defilles, Alexandru Saveanu, Amira Mohamed, Dominique Figarella-Branger, Pierre-Hugues Roche, Stéphane Fuentes, Olivier Chinot, Henry Dufour,[...]. J Neurosurg 2017
27
33

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study.
J W Goodwin, J Crowley, H J Eyre, B Stafford, K A Jaeckle, J J Townsend. J Neurooncol 1993
98
18

Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial.
Nicolas Marincek, Piotr Radojewski, Rebecca A Dumont, Philippe Brunner, Jan Müller-Brand, Helmut R Maecke, Matthias Briel, Martin A Walter. J Nucl Med 2015
36
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.